Market News Call

Latest Developments: Baidu Inc (ADR) (NASDAQ:BIDU), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Lakeway, NY — (MARKET NEWS CALL) — 11/01/2013 —, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Baidu Inc (ADR) (NASDAQ:BIDU), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT).

Baidu Inc (ADR) (NASDAQ:BIDU) shares declined 2.51% to $160.80. The company is buying companies to accelerate its transition to mobile devices, where traffic is at least doubling annually, Chief Executive Officer Robin Li said on Oct. 31.

Should Investors Buy BIDU After Yesterday’s Slump? Find Out Here

Additionally, the company on Oct. 29 announced its unaudited financial results for the third quarter ended September 30, 2013. Total revenues in the third quarter of 2013 were RMB8.892 billion ($1.453 billion), a 42.3% increase from the corresponding period in 2012. Net income attributable to Baidu in the third quarter of 2013 was RMB3.048 billion ($498.0 million), a 1.3% increase from the corresponding period in 2012.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares plunged 44.44% to $2.20. The company on Oct. 31 said it is suspending sales of its leukemia drug Iclusig because of concerns that patients could suffer from blood clots. The company said that the Food and Drug Administration asked it to stop marketing the drug Wednesday afternoon. The company is negotiating with the FDA about changes to prescribing information and new ways to manage the risks associated with Iclusig. Ariad said it wants to resume marketing the drug.

Can Traders Buy ARIA After The Solid Rally? Get Free Trend Analysis Here

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) stock gained 8.19% to $3.04. Phyxius Pharma, Inc. and Oxygen Biotherapeutics, Inc., (OXBT), on Oct. 30 announced that researchers at the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, recently published findings of a meta-analysis of multiple clinical trials that evaluated the use of levosimendan in patients undergoing heart surgery. The study aggregated and analyzed results from 14 independent clinical trials with a total of 1,155 patients.

Should Investors Rush To Buy OXBT After The Solid Rally? Get Special Report Here

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Tags: , , , ,

Leave your comment here